DK1049465T3 - Anvendelse af inhibitorer til behandling af RTK-hyperfunktionsbetingede forstyrrelser, især af kræft - Google Patents

Anvendelse af inhibitorer til behandling af RTK-hyperfunktionsbetingede forstyrrelser, især af kræft

Info

Publication number
DK1049465T3
DK1049465T3 DK99903669T DK99903669T DK1049465T3 DK 1049465 T3 DK1049465 T3 DK 1049465T3 DK 99903669 T DK99903669 T DK 99903669T DK 99903669 T DK99903669 T DK 99903669T DK 1049465 T3 DK1049465 T3 DK 1049465T3
Authority
DK
Denmark
Prior art keywords
hyperfunction
rtk
inhibitors
treat
related disorders
Prior art date
Application number
DK99903669T
Other languages
English (en)
Inventor
Axel Ullrich
Johannes Bange
Pjotr Knyazev
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7855380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1049465(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK1049465T3 publication Critical patent/DK1049465T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK99903669T 1998-01-22 1999-01-22 Anvendelse af inhibitorer til behandling af RTK-hyperfunktionsbetingede forstyrrelser, især af kræft DK1049465T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19802377A DE19802377A1 (de) 1998-01-22 1998-01-22 Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
PCT/EP1999/000405 WO1999037299A1 (de) 1998-01-22 1999-01-22 Verwendung von inhibitoren für die behandlung von rtk-überfunktions-bedingten störungen, insbesondere von krebs

Publications (1)

Publication Number Publication Date
DK1049465T3 true DK1049465T3 (da) 2007-02-05

Family

ID=7855380

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99903669T DK1049465T3 (da) 1998-01-22 1999-01-22 Anvendelse af inhibitorer til behandling af RTK-hyperfunktionsbetingede forstyrrelser, især af kræft

Country Status (11)

Country Link
US (4) US6770742B1 (da)
EP (1) EP1049465B1 (da)
JP (3) JP2002518292A (da)
CN (2) CN100444838C (da)
AT (1) ATE342056T1 (da)
AU (1) AU756378B2 (da)
CA (1) CA2319121A1 (da)
DE (2) DE19802377A1 (da)
DK (1) DK1049465T3 (da)
ES (1) ES2274616T3 (da)
WO (1) WO1999037299A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19802377A1 (de) 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
US6306119B1 (en) * 1999-01-20 2001-10-23 Pearl Technology Holdings, Llc Skin resurfacing and treatment using biocompatible materials
EP1332761A1 (en) * 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agonists of fibroblast growth factor receptors (FGFR)
JP2005530687A (ja) * 2002-01-31 2005-10-13 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｆｇｆｒアゴニスト
ES2336832T3 (es) 2005-07-22 2010-04-16 Five Prime Therapeutics, Inc. Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr.
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US8394927B2 (en) 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
US8216783B2 (en) * 2008-04-14 2012-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors
CN102171343B (zh) * 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
US8278105B2 (en) * 2008-09-09 2012-10-02 University Of Southern California Induction, propagation and isolation of liver progenitor cells
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWING PROCEDURES USING EXTRACELLULAR FGFR4 DOMAINS
CA2780457A1 (en) 2009-11-13 2011-05-19 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP6576325B2 (ja) 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー ヘテロアリール化合物およびそれらの使用
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
KR102901842B1 (ko) * 2017-08-11 2025-12-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 전이의 치료를 위한 키나제의 표적화
EA202190826A1 (ru) * 2018-09-21 2021-06-16 Янссен Фармацевтика Нв Лечение холангиокарциномы

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988617A (en) * 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
JPH03297390A (ja) * 1990-04-13 1991-12-27 Fujisawa Pharmaceut Co Ltd Ｆｒ９０１３６２物質、その製法及び用途
DE4104240A1 (de) * 1991-02-12 1992-08-13 Speyer Georg Haus Chemo Klonierung eines neuen mitgliedes der familie der fibroblasten-wachstumsfaktoren (fgf)-rezeptoren
AU690644B2 (en) 1994-02-14 1998-04-30 Rijksuniversiteit Leiden A method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C
US5866323A (en) 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
US5766851A (en) 1995-05-19 1998-06-16 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type II diabetes mellitus
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
AU7622698A (en) * 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
CA2289102A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
DE19802377A1 (de) 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs

Also Published As

Publication number Publication date
JP5732109B2 (ja) 2015-06-10
CN100444838C (zh) 2008-12-24
ES2274616T3 (es) 2007-05-16
CA2319121A1 (en) 1999-07-29
ATE342056T1 (de) 2006-11-15
WO1999037299B1 (de) 1999-10-28
US7297774B2 (en) 2007-11-20
US20040067885A1 (en) 2004-04-08
DE59913907D1 (de) 2006-11-23
US7678372B2 (en) 2010-03-16
US8043806B2 (en) 2011-10-25
JP5512935B2 (ja) 2014-06-04
US20100184686A1 (en) 2010-07-22
JP2002518292A (ja) 2002-06-25
EP1049465B1 (de) 2006-10-11
AU756378B2 (en) 2003-01-09
CN1291096A (zh) 2001-04-11
CN101474398A (zh) 2009-07-08
WO1999037299A1 (de) 1999-07-29
EP1049465A1 (de) 2000-11-08
JP2009001549A (ja) 2009-01-08
DE19802377A1 (de) 1999-08-19
US20040235776A1 (en) 2004-11-25
JP2013231048A (ja) 2013-11-14
US6770742B1 (en) 2004-08-03
AU2423999A (en) 1999-08-09

Similar Documents

Publication Publication Date Title
ATE342056T1 (de) Verwendung von inhibitoren für die behandlung von rtk-überfunktions-bedingten störungen, insbesondere von krebs
RU2408735C2 (ru) Способ предсказания ответа на лечение
Chu et al. Keratin expression in human tissues and neoplasms
Espineda et al. Analysis of the Na, K‐ATPase α‐and β‐subunit expression profiles of bladder cancer using tissue microarrays
DE69921982D1 (de) Neuartiges verfahren zur identifizierung von klonen mit einer gewünschten biologischen eigenschaft, ausgehend von einer expressionsgenbank
ATE269416T1 (de) Verwendung von vereinigten sonden zur genetischen analyse
Klein et al. SERPINE 1 expression discriminates site‐specific metastasis in human melanoma
DK1482041T3 (da) NL6-TIE-receptor-tyrosinkinase-ligand-homolog
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
IL122808A0 (en) Kit for detecting genetic predisposition for osteoporosis
EP0970372A4 (en) EVIDENCE OF DISEASE-RELATED INFORMATION OF A PROTEIN
DK1454992T3 (da) Anaplastisk lymfomakinaseassay, reagenser og sammensætninger deraf
ATE245197T1 (de) Entwurf diskontinuierlicher sonden unter verwendung von hybritopemapping
ATE403743T1 (de) Genetische veränderungen, die mit lungencarzinomen korrelieren
PT1994410E (pt) Métodos e estojos para detecção precoce de cancro ou de predisposição a este
EP1183390A4 (en) METHODS FOR PREDICTING A PREGNANCY RESULT FROM A TEST PERSON WITH THE HELP OF AN HCG TEST
AU3624199A (en) Quantitative method for detecting nucleotide concentration
Böhm et al. Hyaluronan expression in differentiated thyroid carcinoma
DK0972075T3 (da) Fremgangsmåder til vurdering af kardiovaskulær status og sammensætning til anvendelse deraf
WO2004077057A8 (en) Standard for immunohistochemistry, immunocytochemistry and molecular cytogenetics
Adair et al. High-mobility group A1 proteins inhibit expression of nucleotide excision repair factor xeroderma pigmentosum group A
Long et al. Why and how immunohistochemistry should now be used to screen for the BRAFV 600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France)
WO2003073821A3 (en) Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER
DE60130565D1 (de) Pde8a und seine verwendung
Kawano et al. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer